Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronghui Xu

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 5, 2025
A Response to the Letter to the Editor: Refining Risk and Redefining Stage: Hidden Implications of BAP1-Mutant Mesothelioma Shiuan-Chih Chen, MD, PhD; Yuan-Ti Lee, MD, PhDMichele Carbone, Michael Minaai, Muaiad Kittaneh, et al.
International Journal of Radiation Oncology, Biology, Physics|August 22, 2021
Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III TrialCasey W Williamson, Igor Sirák, Ronghui Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 24, 2021
BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestosFlavia Novelli, Angela Bononi, Qian Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2023
HMGB1 released by mesothelial cells drives the development of asbestos-induced mesotheliomaJoelle S Suarez, Flavia Novelli, Keisuke Goto, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 2020
Heterozygous germline <i>BLM</i> mutations increase susceptibility to asbestos and mesotheliomaAngela Bononi, Keisuke Goto, Guntulu Ak, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2023
BAP1 is a novel regulator of HIF-1αAngela Bononi, Qian Wang, Alicia A Zolondick, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2017
Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)Loren K Mell, Igor Sirák, Lichun Wei, et al.
JAMA|February 8, 2018
Prevalence of Fetal Alcohol Spectrum Disorders in 4 US CommunitiesPhilip A May, Christina D Chambers, Wendy O Kalberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 5, 2025
A Response to the Letter to the Editor: Refining Risk and Redefining Stage: Hidden Implications of BAP1-Mutant Mesothelioma Shiuan-Chih Chen, MD, PhD; Yuan-Ti Lee, MD, PhDMichele Carbone, Michael Minaai, Muaiad Kittaneh, et al.
International Journal of Radiation Oncology, Biology, Physics|August 22, 2021
Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III TrialCasey W Williamson, Igor Sirák, Ronghui Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 24, 2021
BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestosFlavia Novelli, Angela Bononi, Qian Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2023
HMGB1 released by mesothelial cells drives the development of asbestos-induced mesotheliomaJoelle S Suarez, Flavia Novelli, Keisuke Goto, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 2020
Heterozygous germline <i>BLM</i> mutations increase susceptibility to asbestos and mesotheliomaAngela Bononi, Keisuke Goto, Guntulu Ak, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2023
BAP1 is a novel regulator of HIF-1αAngela Bononi, Qian Wang, Alicia A Zolondick, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2017
Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)Loren K Mell, Igor Sirák, Lichun Wei, et al.
JAMA|February 8, 2018
Prevalence of Fetal Alcohol Spectrum Disorders in 4 US CommunitiesPhilip A May, Christina D Chambers, Wendy O Kalberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Pageof 15